Anthem, Sarepta Therapeutics sales and marketing update

Anthem said it will not cover Exondys 51 eteplirsen from Sarepta to treat Duchenne muscular dystrophy (DMD) because it said the therapy is “investigational and not medically necessary.” Last month, F...